Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital are First in State to Offer Innovative Targeted Treatment for Rare Neuroendocrine Tumors

Rutgers Cancer Institute of New Jersey, in collaboration with Robert Wood Johnson University Hospital (RWJUH) - New Brunswick, is the first in the Garden State to administer a form of targeted cancer treatment known as peptide receptor radionuclide therapy (PRRT) for rare neuroendocrine tumors that have spread beyond the initial tumor site.

Provided by EUPB - Read the full story at the source site.
Read The Full Story

Top News